Corium

Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
COGS, ATM, Agile, Net, Conference, GAAP, Growth, Woman, Therapy, Table, Second, Cryptocurrency, Clothing, Video game, Food delivery, Bank, Contraceptive patch, Corium, Pandia

ET

Key Points: 
  • ET
    PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today reported financial results for the three and nine months ended September 30, 2023, and provided a corporate update.
  • Twirla demand for the third quarter 2023 was 74,325 total cycles, a 33% increase from the second quarter 2023 and a 147% increase from the third quarter 2022.
  • Retail demand, which is the Company’s most profitable channel, was 40,196 total cycles in the third quarter 2023, a 13% increase from the second quarter 2023.
  • Non-retail demand for the third quarter 2023 was 34,129 total cycles and an increase of 71% from the second quarter 2023.

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

Retrieved on: 
Friday, October 6, 2023
Biotechnology, Natural Resources, Pharmaceutical, Finance, Health, Mental Health, Professional Services, Cannabis, Master of Arts, Investment, Senior, Warburg Pincus, Bachelor of Economics, Master of Business Administration, Goldman Sachs, Stanford University, Spectrum Pharmaceuticals, J. P. Morgan, Medication, Corporate finance, Economics, Business administration, ACI, Pharmaceutical industry, Management, Genentech, Corium

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) ("Anebulo"), today announced the appointment of Bimal Shah to its Board of Directors.

Key Points: 
  • Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) ("Anebulo"), today announced the appointment of Bimal Shah to its Board of Directors.
  • Mr. Shah will serve as a member of the board’s audit and compensation committees.
  • "I am pleased to welcome Bimal to the Anebulo Board," said Dr. Joseph Lawler, Anebulo’s Chairman.
  • Mr. Shah previously held business development, finance, and strategic commercial roles at Spectrum Pharmaceuticals and Genentech (part of Roche).

Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across Asia

Retrieved on: 
Thursday, August 10, 2023
Health, Genetics, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, Hypersensitivity, Cholinesterase, Nausea, Bethanechol, Bradycardia, Peptic ulcer disease, Asthma, Neuromuscular blocking agents, Cholinergic, Partnership, Alzheimer's disease, Diarrhea, Gastrointestinal tract, IQVIA, Roflumilast, Skin, History, Orthostatic syncope, CNS, Heart block, Dementia, Tablet, Anesthesia, Vomiting, Enzyme inhibitor, Incidence, Patient, Chloride, Gastrointestinal bleeding, Nonsteroidal anti-inflammatory drug, FDA, Relaxation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cholinesterase inhibitor, Safety, Food, Caregiver, Pharmaceutical industry, Residential care, Dietary supplement, Corium, Donepezil, Lotus

Corium, LLC (“Corium”), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Lotus Pharmaceutical (1795:TT; “Lotus”), a multinational pharmaceutical company, announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY® (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.

Key Points: 
  • Corium, LLC (“Corium”), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Lotus Pharmaceutical (1795:TT; “Lotus”), a multinational pharmaceutical company, announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY® (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.
  • The companies expect to file for regulatory approval in some Asian markets later this year.
  • Under the terms of the agreement, Lotus will have exclusive rights to commercialize ADLARITY® in the applicable territory and will be responsible for the regulatory approval process.
  • According to IQVIA data, the market size of donepezil in the 10 markets in the territory is USD 185 Million.

Journal Frontiers in Psychiatry Publishes Analysis of Open Label Safety Study Showing Improvements in Sleep Habits for Children With ADHD After Treatment With AZSTARYS® (serdexmethylphenidate and dexmethylphenidate)

Retrieved on: 
Monday, June 26, 2023
Central nervous system, Frontiers, Gastrointestinal tract, Speech, Overalls, Sleep, Children's Sleep Habits Questionnaire, ADHD, Medicine, CNS, Movement, Parasomnia, Schedule, Attention deficit hyperactivity disorder, Insomnia, Hydrogen chloride, MD, Patient, Central nervous system disease, Sleep disorder, Rapid eye movement sleep behavior disorder, Molar, Washington University School of Medicine, Somnolence, SDX, Ageing, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Caregiver, Safety, Dietary supplement, Pharmaceutical industry, Corium, Psychiatry

BOSTON, June 26, 2023 /PRNewswire/ -- Corium, LLC, a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today that the peer-reviewed journal Frontiers in Psychiatry published an analysis of a yearlong open-label safety study of Corium's attention-deficit hyperactivity disorder (ADHD) medicine AZSTARYS (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]). AZSTARYS was approved by the U.S. Food and Drug Administration in 2021 for the treatment of ADHD symptoms in people aged 6 years through adulthood. The analysis showed that study participants, children aged 6 to 12 years with ADHD and treated with AZSTARYS for up to twelve months, had statistically significant and lasting improvements in their sleep as assessed by the Children's Sleep Habits Questionnaire (CSHQ), a caregiver-reported screening survey designed to assess behavioral and medically based sleep problems in school children.

Key Points: 
  • AZSTARYS was approved by the U.S. Food and Drug Administration in 2021 for the treatment of ADHD symptoms in people aged 6 years through adulthood.
  • Almost three in four children with ADHD have some sleep impairment, according to Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD), a national nonprofit organization serving people affected by ADHD.
  • After one month of AZSTARYS treatment, the children's average CSHQ total sleep disturbance score significantly decreased, indicating improved sleep.
  • Moreover, after 12 months of treatment their average CSHQ total score remained in the 48.9 to 50.1 range, indicating the children sustained overall sleep improvements while receiving AZSTARYS.

Corium to Report Positive Data on ADHD Medication AZSTARYS® (serdexmethylphenidate and dexmethylphenidate) at 2023 American Neuropsychiatric Association Annual Meeting and at 2023 National Association of Pediatric Nurse Practitioners Conference

Retrieved on: 
Monday, March 13, 2023
CNS, Research, American Neuropsychiatric Association, Ageing, SDX, Pediatric nurse practitioner, Conference, ANPA, Gastrointestinal tract, Patient, Central nervous system, National Medical Association, ADHD, Sleep, Safety, National Conference, EDT, Poster, National Association, Copley Place, Dietary supplement, Nursing, Corium

BOSTON, March 13, 2023 /PRNewswire/ -- Corium, LLC, a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announces the upcoming presentation of positive data about its first-in-class attention-deficit hyperactivity disorder (ADHD) medicine AZSTARYS (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) at two national medical association meetings this month.

Key Points: 
  • AZSTARYS data includes durable ADHD symptom improvement, improved sleep, and real world claims analysis
    Azstarys is the first and only once-daily treatment for ADHD symptoms containing SDX, the prodrug of d-MPH.
  • This formulation provides control of ADHD symptoms both rapidly with the immediate-release d-MPH and for an extended duration with SDX.
  • "Our participation at the 2023 annual meetings of the American Neuropsychiatric Association and the National Association of Pediatric Nurse Practitioners also embody Corium's ongoing commitment to research and share scientific knowledge as a leader in the CNS therapeutic space."
  • Corium's two posters at the National Association of Pediatric Nurse Practitioner's 44th National Conference on Pediatric Health Care (NAPNAP) meeting will be presented on Wednesday, March 15 from 12:30 to 1:30 p.m. at the Rosen Shingle Creek in Orlando, FL.

Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates

Retrieved on: 
Tuesday, March 7, 2023
Corporation, History, Zebra, PDUFA, Growth, New Drug Application, Investment, Medical Affairs Bureau, Niemann–Pick disease, EAP, Acquisition, NDA, Therapy, Business development, Safety, Corium, Rare, Webcast, Conference call, Conference, Depreciation, R, Legal Affairs, Disease, Collection, Research, Idiopathic hypersomnia, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, NPC, G&A, IH, Food, SDX, Senior, Exercise, Broadcasting, Pharmaceutical industry, Sales, Management, Cryptocurrency

ET

Key Points: 
  • ET
    Strong balance sheet with cash, cash equivalents and investments of $102.9 million which extends the cash runway into 2026
    CELEBRATION, Fla., March 07, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra,” or “the Company,” formerly “KemPharm, Inc.”), a rare disease therapeutics company, today reported its financial results for the fourth quarter and year ended December 31, 2022.
  • “Zevra is a company transformed, with a new strategic purpose to deliver novel therapeutics to patients with rare diseases,” said Richard W. Pascoe, Chief Executive Officer of Zevra Therapeutics.
  • Overview of Fourth Quarter (Q4) and Full-Year (FY) 2022 Financial Results:
    Net revenue for Q4 2022 was $2.3 million, as compared to Q4 2021 net revenue of $2.6 million.
  • ET, to discuss its corporate and financial results for the fourth quarter and full-year 2022.

Corium Pharma Solutions Names Suzanne Hinchliffe as Chief People Officer

Retrieved on: 
Wednesday, March 1, 2023
Communications manager, NYSE, Acquisition, Risk, Crest Whitestrips, Truist, Growth, PG, Human resources, HR, BB&T, Human, Pharmaceutical industry, Management, Corium

GRAND RAPIDS, Mich., March 1, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Suzanne Hincliffe as Chief People Officer.   This announcement follows the recent appointments of several industry veterans to CPSI, Mark Sirgo as Chief Executive Officer, Ernie De Paloantonio as Chief Financial Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer.

Key Points: 
  • GRAND RAPIDS, Mich., March 1, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Suzanne Hincliffe as Chief People Officer.
  • This announcement follows the recent appointments of several industry veterans to CPSI, Mark Sirgo as Chief Executive Officer, Ernie De Paloantonio as Chief Financial Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer.
  • As Chief People Officer, Suzanne will manage all aspects of human resources including talent acquisition; total rewards; performance; payroll; and HR operations, compliance, and risk.
  • Founded in 1995 in Grand Rapids, Michigan, Corium Pharma Solutions has maintained longstanding partnerships with multinational Fortune 500 companies and pharmaceutical businesses alike.

Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy

Retrieved on: 
Monday, February 27, 2023
Safety, Therapy, Quality of life, Annual, Disease, Drug development, Annual general meeting, FDA, Investment, Patient, Growth, Ageing, Corium, KMPH, History, Niemann–Pick disease, Idiopathic hypersomnia, New Drug Application, ADHD, Annual Meetings of the International Monetary Fund and the World Bank Group, Pharmaceutical industry, Shareholder, Zebra

With the re-election of these serving directors, the Zevra Board will comprise seven highly qualified individuals, five of whom are independent and each of whom is actively engaged in overseeing Zevra’s transformation into a commercially driven rare disease therapeutics company.

Key Points: 
  • With the re-election of these serving directors, the Zevra Board will comprise seven highly qualified individuals, five of whom are independent and each of whom is actively engaged in overseeing Zevra’s transformation into a commercially driven rare disease therapeutics company.
  • “Our name change and new Zevra brand are key steps in advancing our company’s focus on rare disease therapeutic research, development and commercialization,” said Matthew R. Plooster, Chairman of the Zevra Board of Directors.
  • Proxy battles can be costly and distracting, and as such, I intend to vote in favor of the Zevra slate.
  • The Zevra Board recommends that stockholders discard any proxy materials from Daniel Mangless and vote using the WHITE proxy card they will receive as part of the definitive proxy materials that will be delivered by the Company.

Corium Pharma Solutions Names Ernie De Paolantonio as Chief Financial Officer

Retrieved on: 
Wednesday, February 15, 2023
CFO, Treasurer, Crest Whitestrips, PG, NYSE, Therapy, Information technology, Ernie, Growth, Teligent Telecom, Pharmaceutical industry, Management, Corium

GRAND RAPIDS, Mich., Feb. 15, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Ernie De Paolantonio as Chief Financial Officer. This announcement follows the recent appointments of several industry veterans, Mark Sirgo as Chief Executive Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer.

Key Points: 
  • GRAND RAPIDS, Mich., Feb. 15, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Ernie De Paolantonio as Chief Financial Officer.
  • This announcement follows the recent appointments of several industry veterans, Mark Sirgo as Chief Executive Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer.
  • Prior to that, he held several leadership positions throughout his career including Chief Financial Officer at Teligent, Inc., a specialty generic pharmaceutical company, Fortovia Therapeutics Inc., a privately held healthcare company, Chief Financial Officer, Secretary and Treasurer of BioDelivery Sciences International, Inc., a public specialty pharmaceutical company and Chief Financial Officer of CorePharma LLC, a privately held specialty generic company.
  • Ernie will bring his over thirty years of financial experience across a spectrum of pharmaceutical companies to help drive the growth of Corium Pharma Solutions.

Corium Pharma Solutions Names Two Industry Veterans to its Executive Team

Retrieved on: 
Thursday, February 9, 2023
Saint Joseph's University, Niraj, ApiJect Systems, Therapy, Alzheimer's disease, Rare, International business, Crest Whitestrips, Publication, Intellectual property, PG, NYSE, State university system, Acquisition, Patient, Business, Business development, University, Research, Rensselaer Polytechnic Institute, Temple University School of Pharmacy, Area under the curve (pharmacokinetics), FDA, Growth, Avior, MS, BS, Indian Institutes of Technology, Chemical engineering, Management, Pharmaceutical industry, Pharmacy, Biology, Corium

GRAND RAPIDS, Mich., Feb. 9, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer.  These appointments, including CPSI's recent announcement that Mark Sirgo had been named Chief Executive Officer, further strengthen CPSI's executive team and position the company for long-term growth.

Key Points: 
  • These appointments, including CPSI's recent announcement that Mark Sirgo had been named Chief Executive Officer, further strengthen CPSI's executive team and position the company for long-term growth.
  • Dr. Niraj Vasisht brings more than 25 years of experience as an executive, entrepreneur, and technology key-opinion-leader in drug delivery to the pharmaceutical industry.
  • As Chief Technology Officer, Niraj will play a critical role overseeing the formulation development work behind all of our CPSI platforms.
  • Founded in 1995 in Grand Rapids, Michigan, Corium Pharma Solutions has maintained longstanding partnerships with multinational Fortune 500 companies and pharmaceutical businesses alike.